Kankaanranta, Hannu
Ilmarinen, Pinja
Kankaanranta, Terhi
Tuomisto, Leena E
Article History
Received: 10 December 2014
Revised: 29 April 2015
Accepted: 12 May 2015
First Online: 25 June 2015
Competing interests
: HK reports personal fees and non-financial support from Almirall, personal fees from AstraZeneca, personal fees from Chiesi Pharma AB, personal fees from GlaxoSmithKline, personal fees and non-financial support from Boehringer-Ingelmheim, personal fees from Leiras-Takeda, personal fees from MSD (Merck Sharp & Dohme Corp.), personal fees from Novartis, personal fees from Mundipharma, personal fees from Medith, personal fees from Resmed Finland and non-financial support from Intermune, outside the submitted work. LET reports personal fees and non-financial support from Leiras-Takeda, personal fees and non-financial support from Mundipharma, personal fees and non-financial support from Novartis, and non-financial support from Boehringer-Ingelheim, outside the submitted work. The other authors declare no conflicts of interest.